A post hoc pooled data analysis to evaluate the gastrointestinal tolerability profile of tapentadol extended release (ER) versus oxycodone controlled release (CR) in patients ≥75 years of age

2011 ◽  
Vol 12 (4) ◽  
pp. P56 ◽  
Author(s):  
D. Biondi ◽  
J. Xiang ◽  
M. Etropolski ◽  
B. Moskovitz
Keyword(s):  
Data Analysis ◽  
Controlled Release ◽  
Extended Release ◽  
Tolerability Profile ◽  
Pooled Data ◽  
Gastrointestinal Tolerability ◽  
Post Hoc

Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan

2020 ◽  
Vol 53 (03) ◽  
pp. 122-132
Author(s):  
Taro Kishi ◽  
Reiji Yoshimura ◽  
Yuki Matsuda ◽  
Kenji Sakuma ◽  
Nakao Iwata
Keyword(s):  
Systematic Review ◽  
Extended Release ◽  
Tolerability Profile ◽  
Phase 3 ◽  
Double Blind ◽  
Acute Schizophrenia ◽  
Pooled Data ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Paliperidone Extended Release

Abstract Introduction The use of the blonanserin patch (BLO-P) for schizophrenia treatment was approved in Japan in 2019. This systematic review of trials in Japan assessed the efficacy and safety profile of BLO-P compared with other antipsychotics. Methods The systematic review included 6-week, double-blind, randomized, placebo-controlled, phase 3 trials in Japan that included patients with acute schizophrenia. Pooled data for patients receiving BLO-P 40 and 80 mg/day (BLO-P40+80) were compared with pooled data for patients receiving asenapine 10 and 20 mg/day (ASE10+20) and data for those receiving brexpiprazole 2 mg/day (BRE2) and paliperidone extended-release 6 mg/day (PAL-ER6). Results All the investigated treatments were superior to placebo in reducing the Positive and Negative Syndrome Scale (PANSS) total score; the Hedges’ g values (95% confidence interval) for BLO-P40+80, ASE10+20, BRE2, and PAL-ER6 were−0.40 (−0.58,−0.22),−0.61 (−0.79,−0.42),−0.33 (−0.60,−0.07), and−0.69 (−0.93,−0.45), respectively. There were differences among the antipsychotics in the incidence of various individual adverse events. Discussion BLO-P40+80 may have a good efficacy/safety/tolerability profile for the treatment of patients with acute schizophrenia.

1097-P: Glycemic Control and Safety Profile of Insulin Glargine 300 U/mL in Older Adults—REALI Pooled Data Analysis

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1097-P
Author(s):  
RICCARDO C. BONADONNA ◽  
DIDAC MAURICIO ◽  
DIRK MÜLLER-WIELAND ◽  
NICK FREEMANTLE ◽  
GREGORY BIGOT ◽  
...  
Keyword(s):  
Older Adults ◽  
Data Analysis ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Safety Profile ◽  
Pooled Data

scholarly journals Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis

2021 ◽  
Author(s):  
Riccardo C. Bonadonna ◽  
Didac Mauricio ◽  
Dirk Müller-Wieland ◽  
Nick Freemantle ◽  
Gregory Bigot ◽  
...  
Keyword(s):  
Data Analysis ◽  
Insulin Glargine ◽  
Pooled Data

scholarly journals Nicotine pharmacokinetics of electronic cigarettes: A pooled data analysis from the literature

2021 ◽  
Vol 8 ◽  
pp. 84-95
Author(s):  
Karin Jacobson ◽  
Javier Martinez ◽  
Sylvain Larroque ◽  
Ian W. Jones ◽  
Thilo Paschke
Keyword(s):  
Data Analysis ◽  
Electronic Cigarettes ◽  
Pooled Data ◽  
Nicotine Pharmacokinetics
Sign in / Sign up

Export Citation Format

Share Document